Tetraphase eyes partnership or float to take eravacycline into Phase III
This article was originally published in Scrip
Executive Summary
Ahead of fundraising or partnership negotiations to finance Phase III development, Tetraphase Pharmaceuticals unveiled positive Phase II clinical trial data for its lead drug candidate, the intravenous broad-spectrum antibiotic eravacycline (TP-434), in the treatment of complicated intra-abdominal infections (cIAIs) in a trial against ertapenem.